By Julie Steenhuysen CHICAGO (Reuters) - Adding an experimental mRNA-based vaccine from Moderna (NASDAQ:MRNA) Inc and Merck & Co reduced the risk that the most deadly skin...
By Ludwig Burger FRANKFURT (Reuters) - Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage,...
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
Better-than-expected results for the week once again lift S&P 500 EPS growth for Q1 2023, now set to come in at -2.2% Potential earnings surprises this week: PerkinElmer (PKI),...
The Federal Reserve is widely expected to raise interest rates by 25 basis points this week. In this piece, I will highlight ten stocks well placed to ride out further turmoil in...
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
| Average | 46.68 (+20.03% Upside) |
| High | 75.00 |
| Low | 35.00 |
| Price | 38.89 |
| No. of Analysts | 26 |
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Neutral |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 7.76 | 7.97 | 7.58 | -0.12 | -1.52% | 46.91M | NYSE | |||
| 1.73 | 1.83 | 1.70 | -0.04 | -2.26% | 20.88M | NASDAQ | |||
| 5.40 | 6.89 | 5.07 | -0.54 | -9.09% | 389.70K | NASDAQ | |||
| 9.67 | 10.06 | 9.66 | -0.040 | -0.41% | 851.53K | NYSE | |||
| 1.20 | 1.20 | 1.155 | +0.020 | +1.69% | 383.63K | NASDAQ | |||
| 11.00 | 11.00 | 11.00 | -2.61 | -19.18% | 0.00 | OTC Markets | |||
| 122.94 | 129.55 | 122.63 | -4.97 | -3.89% | 32.88M | NASDAQ | |||
| 5.28 | 5.37 | 5.00 | +0.34 | +6.88% | 804.19K | NASDAQ | |||
| 21.02 | 21.08 | 20.31 | +0.88 | +4.37% | 1.52M | NYSE | |||
| 103.48 | 108.43 | 103.42 | -3.51 | -3.28% | 941.26K | NYSE | |||
| 155.59 | 162.46 | 155.46 | -4.09 | -2.56% | 3.33M | NYSE | |||
| 31.31 | 31.36 | 30.80 | +0.23 | +0.74% | 10.56M | NASDAQ | |||
| 15.67 | 15.70 | 15.62 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 49.39 | 49.86 | 49.39 | -0.61 | -1.22% | 2.09K | OTC Markets | |||
| 36.95 | 37.53 | 36.61 | -0.80 | -2.12% | 10.82M | NASDAQ |